ChiCTR2600118157 版本V1.1 版本创建时间2026/02/05 12:02:48 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118157 

最近更新日期:

Date of Last Refreshed on:

2026-02-02 17:53:08 

注册时间:

Date of Registration:

2026-02-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

奥沙西泮与地西泮治疗酒依赖急性戒断症状的疗效与安全性比较:一项多中心实用性随机对照研究(pRCT)

Public title:

Comparison of the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence A multicenter practical randomized controlled study (pRCT)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

奥沙西泮与地西泮治疗酒依赖急性戒断症状的疗效与安全性比较:一项多中心实用性随机对照研究(pRCT)

Scientific title:

Comparison of the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence A multicenter practical randomized controlled study (pRCT)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王芳芳 

研究负责人:

郝伟 

Applicant:

Wang Fangfang 

Study leader:

Hao Wei 

申请注册联系人电话:

Applicant telephone:

+86 177 0408 9454

研究负责人电话:

Study leader's
telephone:

+86 177 0408 9454

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1945917911@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1945917911@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南长沙人民中路139号

研究负责人通讯地址:

湖南长沙人民中路139号

Applicant address:

139 Middle of Renmin Road, changsha, Hu'nan

Study leader's address:

139 Middle of Renmin Road, changsha, Hu'nan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅二医院

Applicant's institution:

The Second Xiangya Hospital, Central South University

研究负责人所在单位:

中南大学湘雅二医院

Affiliation of the Leader:

The Second Xiangya Hospital, Central South University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LYEC2025-0325

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中南大学湘雅二医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the Second Xiangya Hospital, Central South University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-24 00:00:00

伦理委员会联系人:

陈老师

Contact Name of the ethic committee:

Teacher Cheng

伦理委员会联系地址:

湖南省长沙市人民中路 139 号

Contact Address of the ethic committee:

No. 139, Renmin Middle Road, Changsha City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8529 2476

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学湘雅二医院

Primary sponsor:

The Second Xiangya Hospital, Central South University

研究实施负责(组长)单位地址:

湖南长沙人民中路139号

Primary sponsor's address:

139 Middle of Renmin Road, changsha, Hu'nan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅二医院

具体地址:

湖南长沙人民中路139号

Institution
hospital:

The Second Xiangya Hospital, Central South University

Address:

139 Middle of Renmin Road, changsha, Hu'nan

经费或物资来源:

湖南洞庭药业

Source(s) of funding:

Hunan Dongting Pharmaceutical

研究疾病:

酒精戒断综合征  

Target disease:

AWS

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较奥沙西泮与地西泮在酒依赖急性戒断症状治疗中的疗效与安全性,并重点评估奥沙西泮在肝功能异常患者中的临床优势。  

Objectives of Study:

To compare the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence, and to focus on evaluating the clinical advantages of oxazepam in patients with abnormal liver function.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.住院患者;年龄18-70岁; 2.符合DSM-5酒精使用障碍诊断标准4至4条以上; 3.当前处于戒断期,CIWA-Ar评分≥16分; 4.医生评估适合苯二氮草类药物治疗; 5.签署知情同意书。

Inclusion criteria

1. Inpatients; Aged 18 to 70; 2. Meet four or more of the DSM-5 diagnostic criteria for alcohol use disorder; 3. Currently in the withdrawal period with a CIWA-Ar score of >=16 points; 4. The doctor assesses that benzodiazepines are suitable for treatment. 5. Sign the informed consent form.

排除标准:

1.合并其他物质依赖(除尼古丁); 2.严重精神障碍或认知障碍影响评估; 3.妊娠或哺乳期; 4.对研究药物过敏或禁忌; 5. ALT或AST>500; 6.纽约心功能评级(NYHA)评级≥3级; 7.既往存在HIV感染、自身免疫缺陷患者; 8.无法配合随访或者研究者认为不合适。

Exclusion criteria:

1. Combined with other substance dependencies (except nicotine); 2. Impact assessment of severe mental disorders or cognitive impairments; 3. Pregnancy or lactation period; 4. Allergic to or contraindicated to the investigational drug; 5. ALT or AST>500; 6. New York Cardiac Rating (NYHA) rating >= level 3; 7. Patients with a history of HIV infection or autoimmune deficiency; 8. Inability to cooperate with follow-up or deemed inappropriate by the researcher.

研究实施时间:

Study execute time:

From 2026-02-04 00:00:00 To 2026-02-04 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-04 00:00:00 To 2026-02-04 00:00:00

干预措施:

Interventions:

组别:

地西泮组

样本量:

186

Group:

Diazepam group

Sample size:

干预措施:

口服地西泮治疗,按固定给药方案直至CIWA-Ar评分≤8分后停止用药。

干预措施代码:

Intervention:

Patients in the diazepam group were treated with oral diazepam, following the fixed dosing regimen until the CIWA-Ar score was <=8 points, and then the medication was stopped.administration.

Intervention code:

组别:

奥沙西泮组

样本量:

186

Group:

The oxazepam group

Sample size:

干预措施:

口服奥沙西泮治疗,按固定给药方案直至CIWA-Ar评分≤8分后停止用药。

干预措施代码:

Intervention:

Patients in the oxazepam group were treated with oral oxazepam, following the fixed dosing regimen until the CIWA-Ar score was <=8 points, and then the medication was stopped.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅二院 

单位级别:

三甲 

Institution
hospital:

The Second Xiangya Hospital, Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Annui

City:

单位(医院):

阜阳市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Fuyang Third People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

ANhui

City:

单位(医院):

安徽医科大学附属巢湖医院 

单位级别:

三甲 

Institution
hospital:

Chaohu Hospital Affiliated to Anhui Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市精神卫生中心 

单位级别:

三甲 

Institution
hospital:

Shanghai Mental Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

安徽省精神卫生中心 

单位级别:

三甲 

Institution
hospital:

Anhui Provincial Mental Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

湖南省脑科医院 

单位级别:

三甲 

Institution
hospital:

Hunan Provincial Brain Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京回龙观医院 

单位级别:

三甲 

Institution
hospital:

Beijing Huilongguan Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京安定医院 

单位级别:

三甲 

Institution
hospital:

Beijing Anding Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第六医院 

单位级别:

三甲 

Institution
hospital:

Peking University Sixth Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

武汉市精神卫生中心 

单位级别:

三甲 

Institution
hospital:

Wuhan Mental Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东省精神卫生中心 

单位级别:

三甲 

Institution
hospital:

Shandong Provincial Mental Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东省戴庄医院 

单位级别:

三甲 

Institution
hospital:

Daizhuang Hospital of Shandong Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

潍坊市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Weifang Third People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

青岛市精卫中心 

单位级别:

三甲 

Institution
hospital:

Qingdao Jingwei Cente

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebe

City:

单位(医院):

河北医科大学第一医院 

单位级别:

三甲 

Institution
hospital:

The First Hospital of Hebei Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

东莞市第七人民医院 

单位级别:

三甲 

Institution
hospital:

Dongguan Seventh People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

深圳市康宁医院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Kangning Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省脑科医院 

单位级别:

三甲 

Institution
hospital:

Guangdong Provincial Brain Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

汕头市第四人民医院 

单位级别:

三甲 

Institution
hospital:

Shantou Fourth People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Zhongshan Third People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

河南省精神病医院 

单位级别:

三甲 

Institution
hospital:

Henan Provincial Psychiatric Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

郑州市第九人民医院 

单位级别:

三甲 

Institution
hospital:

Zhengzhou Ninth People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

南阳市第四人民医院 

单位级别:

三甲 

Institution
hospital:

Nanyang Fourth People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京脑科医院 

单位级别:

三甲 

Institution
hospital:

Nanjing Brain Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

苏州广济医院 

单位级别:

三甲 

Institution
hospital:

Suzhou Guangji Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

淮安市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Huai 'an Third People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州市第七人民医院 

单位级别:

三甲 

Institution
hospital:

Wenzhou Seventh People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

湖州市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Huzhou Third People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波大学附属康宁医院 

单位级别:

三甲 

Institution
hospital:

Ningbo University Affiliated Kangning Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

甘肃 

市(区县):

 

Country:

China

Province:

Gansu

City:

单位(医院):

兰州大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Lanzhou University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

大连市第七人民医院 

单位级别:

三甲 

Institution
hospital:

Dalian Seventh People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

CIWA-Ar 评分变化及达到≤8 分的时间

指标类型:

主要指标

Outcome:

Change in CIWA-Ar score and time to reach a score of <=8

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能指标变化趋势

指标类型:

次要指标

Outcome:

Trends in liver function indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

医生判断患者适用两种药物后,采取传统密封信封法进行随机分配(开放标签,不盲法),随机方式RANDARRAY随机排序。

Randomization Procedure (please state who generates the random number sequence and by what method):

After the doctor determines that the patient is suitable for two drugs, the traditional sealed envelope method is used for random allocation (open label, non-blinding method),,Randomly sort by RANDARRAY.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

none

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

CRF

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

CRF

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-02 17:52:27